Gregg Smith

1.1k total citations
15 papers, 377 citations indexed

About

Gregg Smith is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Gregg Smith has authored 15 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Gregg Smith's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Cancer Treatment and Pharmacology (5 papers) and Pain Mechanisms and Treatments (3 papers). Gregg Smith is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Cancer Treatment and Pharmacology (5 papers) and Pain Mechanisms and Treatments (3 papers). Gregg Smith collaborates with scholars based in Australia, United States and France. Gregg Smith's co-authors include Maree T. Smith, Roberta E. Rikli, Christopher J. Burns, J. Andrew Whitney, Markus Seifert, Egon Demetz, Matthew R. Warr, Verena Petzer, Kay‐Uwe Wagner and Günter Weiß and has published in prestigious journals such as Blood, Pain and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Gregg Smith

14 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregg Smith Australia 9 208 163 156 71 65 15 377
Jonathan M. Flanagan United States 10 238 1.1× 227 1.4× 80 0.5× 36 0.5× 38 0.6× 18 403
Enrica Federti Italy 10 175 0.8× 147 0.9× 136 0.9× 11 0.2× 96 1.5× 30 389
Collin Elsea United States 6 170 0.8× 130 0.8× 160 1.0× 68 1.0× 27 0.4× 7 434
Christopher Qian China 11 68 0.3× 116 0.7× 118 0.8× 21 0.3× 35 0.5× 14 365
Kari A. Duck United States 7 77 0.4× 135 0.8× 95 0.6× 10 0.1× 29 0.4× 7 326
Julie Simon United States 8 98 0.5× 72 0.4× 82 0.5× 76 1.1× 234 3.6× 8 429
M. Zucker Israel 12 242 1.2× 255 1.6× 53 0.3× 25 0.4× 26 0.4× 19 497
Kuei-Fu Lin United States 11 127 0.6× 26 0.2× 227 1.5× 16 0.2× 100 1.5× 12 522
Niklas Boknäs Sweden 9 107 0.5× 122 0.7× 103 0.7× 11 0.2× 43 0.7× 18 390
Amandine Perrin Germany 8 56 0.3× 34 0.2× 39 0.3× 55 0.8× 154 2.4× 21 295

Countries citing papers authored by Gregg Smith

Since Specialization
Citations

This map shows the geographic impact of Gregg Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregg Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregg Smith more than expected).

Fields of papers citing papers by Gregg Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregg Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregg Smith. The network helps show where Gregg Smith may publish in the future.

Co-authorship network of co-authors of Gregg Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Gregg Smith. A scholar is included among the top collaborators of Gregg Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregg Smith. Gregg Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Hansen, Ryan J., Bryan Strouse, Kenna Anderes, Gregg Smith, & Christian A. Hassig. (2018). Abstract B181: The Chk1 inhibitor, SRA737, demonstrates chemical synthetic lethality with replication stress-inducing agents, including low-dose gemcitabine, in preclinical models of cancer. Molecular Cancer Therapeutics. 17(1_Supplement). B181–B181. 1 indexed citations
3.
Aßhoff, Malte, Verena Petzer, Matthew R. Warr, et al.. (2017). Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 129(13). 1823–1830. 156 indexed citations
4.
Villeval, Jean‐Luc, Claudine Moratal, Franck Debeurme, et al.. (2013). Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis. Blood. 122(21). 2851–2851. 2 indexed citations
5.
Burge, Matthew, Dusan Kotasek, Gregg Smith, et al.. (2012). Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent. Investigational New Drugs. 31(1). 126–135. 14 indexed citations
6.
Burns, Christopher J., Emmanuelle Fantino, Andrew K. Powell, et al.. (2011). The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In Vivo. Journal of Pharmacology and Experimental Therapeutics. 339(3). 799–806. 12 indexed citations
7.
Pardanani, Animesh, Jason Gotlib, Vikas Gupta, et al.. (2011). An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. Blood. 118(21). 3849–3849. 26 indexed citations
8.
Pardanani, Animesh, Terra L. Lasho, William J. Hogan, et al.. (2010). A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. Blood. 116(21). 460–460. 31 indexed citations
9.
Khong, Tiffany, et al.. (2009). CYT997 Causes apoptosis in human multiple myeloma. Investigational New Drugs. 29(2). 232–238. 11 indexed citations
10.
Powell, Andrew K., et al.. (2009). Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model. Molecular Cancer Therapeutics. 8(12_Supplement). A16–A16. 1 indexed citations
11.
Nicolazzo, Joseph A., Kasiram Katneni, Gregg Smith, et al.. (2008). Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. Journal of Pharmacy and Pharmacology. 60(2). 171–178. 2 indexed citations
12.
Smith, Gregg, R.J. Prankerd, & Maree T. Smith. (1997). Biochemical synthesis, purification and preliminary pharmacological evaluation of normorphine-3-glucuronide. Life Sciences. 61(2). 95–104. 8 indexed citations
13.
Smith, Maree J. & Gregg Smith. (1996). Comments on Smith and Smith (Pain, 62 (1995) 51–60). Pain. 65(2). 286–286. 1 indexed citations
14.
15.
Rikli, Roberta E. & Gregg Smith. (1980). VIDEOTAPE FEEDBACK EFFECTS ON TENNIS SERVING FORM. Perceptual and Motor Skills. 50(3). 895–901. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan M. Flanagan Breakdown of academic impact, for papers by Enrica Federti Breakdown of academic impact, for papers by Collin Elsea Breakdown of academic impact, for papers by Christopher Qian Breakdown of academic impact, for papers by Kari A. Duck Breakdown of academic impact, for papers by Julie Simon Breakdown of academic impact, for papers by M. Zucker Breakdown of academic impact, for papers by Kuei-Fu Lin Breakdown of academic impact, for papers by Niklas Boknäs Breakdown of academic impact, for papers by Amandine Perrin
Rankless by CCL
2026